Eben Tessari - 17 Nov 2025 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Role
CHIEF OPERATING OFFICER
Signature
/s/ Douglas Barry, Attorney-in-Fact
Issuer symbol
KNSA
Transactions as of
17 Nov 2025
Net transactions value
-$456,829
Form type
4
Filing time
19 Nov 2025, 16:38:22 UTC
Previous filing
16 Oct 2025
Next filing
01 Dec 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Tessari Eben CHIEF OPERATING OFFICER C/O KINIKSA PHARMACEUTICALS INTERNATIONA, 105 PICCADILLY, SECOND FLOOR, LONDON, UNITED KINGDOM /s/ Douglas Barry, Attorney-in-Fact 19 Nov 2025 0001867899

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KNSA Class A Ordinary Share Options Exercise $57,395 +6,500 +23% $8.83 35,184 17 Nov 2025 Direct F1
transaction KNSA Class A Ordinary Share Sale $25,852 -645 -1.8% $40.08 34,539 17 Nov 2025 Direct F1, F2
transaction KNSA Class A Ordinary Share Sale $488,372 -11,825 -34% $41.30 22,714 17 Nov 2025 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KNSA Share Option Options Exercise $0 -6,500 -52% $0.000000 6,000 17 Nov 2025 Class A Ordinary Share 6,500 $8.83 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on April 29, 2024.
F2 This transaction was executed in multiple trades through a broker-dealer at prices ranging between $39.61 and $40.585. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F3 This transaction was executed in multiple trades through a broker-dealer at prices ranging between $40.61 and $41.60. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
F4 The option is fully vested and exercisable.